(LML) Manifest against the implementation of U-MDT

 

Leprosy Mailing List – July 27,  2018

Ref.:    (LML) Manifest against the implementation of U-MDT

From:  Joydeepa Darlong and SR. Narahari, India

---

 

Dear Pieter,

 

Clofazemine is not acceptable in children. We force it on MB children and they take it with a great deal of unhappiness. Off record, most mothers confess that their children do not swallow clofazemine. Among those that do discoloration leads to maximum school dropouts and defaults. And we all now that maximum children are PB cases. Its unfair to thrust clofazemine on them.

 

Regards,

 

Joydeepa Darlong

Head Knowledge management

The leprosy Mission Trust India

---

 

Dear Dr Schreuder,

 

Dermatologist Ajit (LML, July 26, 2018) has raised very relevant questions faced in daily practice in India. All of us running small clinics employing a few people who manage a portion of disease burden in the country.

 

Without publications I wish to say presentation has changed and dapsone side effects are increasing. I am seeing a patient presenting with haematuria for two weeks before skin rash. Later high neutrophils persist for a few weeks. Leprosy is not that common in Kerala but yes, it is coming back with more complex presentations and is beginning to challenge the present treatment regimens! 

 

SR Narahari

 

---

LML - S Deepak, B Naafs, S Noto and P Schreuder

LML blog link: http://leprosymailinglist.blogspot.it/

Contact: Dr Pieter Schreuder << editorlml@gmail.com